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Abstract
To study the pathway of degradation of the hepatitis B virus (HBV) middle envelope protein (M), human hepatoblastoma cells were transfected
with a plasmid that specifies production of M in the absence of other viral proteins. When expressed in HepG2 cells, 90% of M protein was secreted
into the culture media within a 24-h period. However, quite surprisingly, 10% of this protein remained cell associated and was only slowly degraded
over a 24–48-h period. Treatment with inhibitors of the cytosolic proteasome complex resulted in the accumulation of full-length HBVMprotein and
M derived HBV-specific polypeptides of 20 and 17 kDa. Treatment with the endoglycosidases PNGase F and Endo H, confirmed that the two species
were derived from a similar polypeptide with a N-linked glycan modification. Evidence that this peptide was derived from a proteolytic processing
event was determined through the detection of the C-terminal fragment using a C-terminal tagged HA tagged construct. The hypothesis that the 20
and 17 kDa polypeptide species are intermediates of M degradation was reinforced by their detection in cells transfected with vectors specifying M
secretion defective mutants that accumulate intracellular M. Moreover, deletion of a putative cleavage sites prevented the detection of the 20 and
17 kDa species, consistent with the notion that they are generated by the action of a cellular protease prior to proteasomal degradation. Thus, these
results highlight an important way in which large protein aggregates, such as the HBsAg can be processed for efficient degradation via the
proteasomes and allow for proper antigen presentation via the MHC I pathway.
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HBV specifies three envelope proteins, called large (L),
middle (M), and small (S), that are all derived from the same
open reading frame (ORF) and may exist as either unglycosy-
lated or N-glycosylated forms (Gerlich et al., 1992). In our
previous work examining the role of N-linked glycan processing
in the folding and degradation of the HBVenvelope proteins, we
have discovered that, under normal conditions, very little of the
HBV M or L protein undergoes degradation through the endo-
plasmic reticular associated degradation (ERAD) and protea-
some pathway (Simsek et al., 2005). The inability to properly
degrade these proteins could have severe clinical consequences,
as reports have indicated that retained HBV envelope proteins⁎ Corresponding author.
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doi:10.1016/j.virol.2007.06.048can stimulate several oncogenic pathways and lead to the
development of HCC (Hsieh et al., 2004; Huang et al., 2005;
Hung et al., 2004; Tai et al., 2002; Wang et al., 2005; Xu et al.,
1997a). Indeed, several reports have shown that many cases of
hepatocellular carcinoma are associated with pre-S1 and pres-S2
mutations that cause accumulation within the ER (Wang et al.,
2006). Thus the poor degradation of these HBV envelope
proteins may have a significant clinical impact.
To study the pathway of degradation of the M and L proteins,
we have attempted to examine the expression and secretion of
these proteins when expressed independently of other HBV
proteins. Analysis of the HBV L protein proved problematic, as
it was associated with toxicity due to the induction of ER stress
(Xu et al., 1997b). Hence our studies were performed using the
HBV M protein. The HBV M protein, like the HBV S protein,
when expressed independently of all other HBV proteins can
form particles and be secreted into the culture medium (Sheu and
Lo, 1994; Shih and Tai, 2004). However, we have discovered
Fig. 1. Pulse chase experiments reveal slow degradation of retained HBV M
protein. (A) HepG2 cells transfected with the pCMV-MS expression construct
were pulsed with 35S -Met/Cys for 1 h followed by 0, 3, 16, 24, or 48 h chase
period. M-specific polypeptides were immunoprecipitated using an antibody to
amino acids 13–26 of the pre-S2 domain. The location of themajorM protein and
S protein species are indicated. (B) HepG2 cells transfected with the pCMV-MS
expression construct were pulsed with 35S -Met/Cys for 1 h followed by 0, 3, or
48 h chase in the absence (left) or presence (right) of the proteasome inhibitor
epoxomicin. Immunoprecipitation was carried out on cell lysates with an
antibody to the preS2 domain. The location of the 36, 33, and 30 kDa HBV M
protein species and the 27 and 24 kDa S species is indicated. The position of
smaller 20 and 17 kDa polypeptides reactive to the pre-S2 antibody are indicated
with the asterisk.
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cell and is slowly degraded over a 24–72-h period. Treatment of
cells transfected with a plasmid that specifies only M, with
inhibitors of the cystolic proteasome complex resulted in the
slight accumulation of full length HBV M protein (36, 33, and
30 kDa) along with the appearance of HBV-specific polypep-
tides of 20 and 17 kDa. To our knowledge, these 20 and 17 kDa
M derived polypeptides have not been reported, previously. The
36, 33, and 20 kDa M species were sensitive to Endo H and
PNGase F, suggesting that these species were N-linked glyco-
forms and had entered the endoplasmic reticulum, the site of
N-linked glycan attachment. Secretion defective expression
vectors that had conserved cysteine residues converted to
alanines produced more of the smaller polypeptides, suggesting
that they may be degradation intermediate(s). Indeed, deletion of
a putative cleavage site prevented the formation of the poly-
peptides. These results highlight an important way in which
large protein aggregates, such as the HBsAg, can be processed
for efficient degradation via the proteasomes and allow for
proper antigen presentation via the MHC I pathway.
Results
In the presence of inhibitors of the proteasome complex, low
molecular weight pre-S2-specific polypeptides are observed in
pulse chase experiments using an M expression vector
To examine the fate of M protein expressed within hepa-
tocytes in tissue culture, we utilized an expression vector that
primarily expressed the HBV M protein in the absence of other
viral gene products. This construct still maintains the ability to
produce a small amount of the S protein, as the internal start
codon has not been removed. The expression vector was
transiently transfected into HepG2 cells and the level of M
protein found in cell lysates determined following a 1-h pulse
with 35S methionine and either a 0-, 3-, 16-, 24-, or 48-h chase.
As Fig. 1 shows, after a 1-h label and 3-h chase, the level of
intracellular M protein is similar to that seen at the 0-h time
point. This implies that no secretion has yet taken place.
Indeed, at this time point, no M protein was detected in the
culture medium (data not shown). However, after a 16-h chase,
the level of intracellular M protein was reduced by 90% as
compared to the 0- and 3-h time points. This coincides with the
appearance of the M protein into the culture medium (data not
shown) suggesting that, as expected, the majority of M protein,
and almost all of the 36 kDa M species is secreted within a 24-h
period. However, a substantial proportion (10%) of the labeled
M protein remained cell associated. This retained M protein
was primarily composed of the unglycosylated and singly
glycosylated M species. Amazingly, the level of this retained
species declined at a slow rate over the 2 day (48 h) chase
period.
The fate of this “detained” protein was studied through the
use of the proteasome inhibitor epoxomicin. Epoxomicin is very
specific for the proteasome and does not inhibit non-proteasomal
proteases such as trypsin, chymotrypsin, papain, cathepsin B,
calpain, or tripeptidyl peptidase II (Schwarz et al., 2000).Therefore the experiment performed in Fig. 1A was performed
again either in the absence (left panel) or in the presence of
epoxomicin (right panel). As epoxomicin was associated with
toxicity past 48 h of treatment, these experiments were only
performed up to 48 h after label. As the right panel of Fig. 1B
shows, although the 36 kDa M species is nearly quantitatively
secreted by 48 h (and is detected in the culture medium, data not
shown), it appears that a small amount of the M protein is being
degraded by the cytosolic proteosome, as a slight accumulation
of full length M protein is seen when the inhibitor is present and
proteasomal degradation is prevented. Thus, proteasomal
degradation of the detained M is slow and/or inefficient, but
does appear to occur.
More surprising is the accumulation of lower bands (20 and
17 kDa) that accumulate predominantly at the later time point in
the presence of the proteasome inhibitor. Thus, preventing
proteasomal degradation allowed for the detection of a new M
species, the 20 and 17 kDa polypeptides. Although these
polypeptides could be seen weakly in the absence of proteasome
inhibitors, significant accumulation was only seen when the
cells were treated with proteasome inhibitor. These fragments
were consistently seen in both our immunoprecipitation
analysis and immunoblot analysis using a pre-S2-specific
antibody when the M protein was expressed and the cells
treated with a variety of proteasome inhibitors (data not shown).
The accumulation of these polypeptides in the presence of
proteasome inhibitors suggests that they are degraded by the
proteasomes. Their accumulation at late time points in pulse
chase experiments also suggests that they are products that arise
from the full-length M species. Taken together, these data imply
that the 20 and 17 kDa M derived polypeptides are precursors to
proteasomal degradation.
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have been in the endoplasmic reticulum
Although the 20 and 17 kDa polypeptides predominantly
appeared at late time points in the pulse chase experiments, it
was possible that they were defective ribosomal products
(DRiPs) rather than a degradation product (Bacik et al., 1997;
Yewdell et al., 1996). To test if these fragments were DRiPs, we
attempted to determine if these fragments were N-glycosylated.
If they are, then it would imply that they have entered the lumen
of the ER, where N-linked glycosylation takes place (Dwek
et al., 2002).
Thus the M expression vector was transfected into HepG2
cells as before and either left untreated or treated with the
proteasome inhibitor lactacystein. Protein lysates were subse-
quently treated with either endoglycosidase PNGase F or Endo
H, and the level of M reactive species was determined by
immunoblot using an antibody specific to amino acids 13–26 of
pre-S2 domain.
PNGase F is an amidohydrolase that cleaves theN-glycosidic
linkage between the core N-acetlyglucosamine and asparagines,
to remove all N-linked oligosaccharides, while Endo Hwill only
remove N-linked glycans containing non-complex type glycans
(Dwek et al., 1993). As Fig. 2A shows, in the untreated sample,
along with the full length 36, 33, and 30 kDaMprotein species, a
small amount of the 20 kDa polypeptide can be seen. Like in
Fig. 1, the 20 kDa species, along with a 17 kDa species, accu-Fig. 2. The degradation intermediate has entered the endoplasmic reticulum. (A) HepG
either left untreated or treated overnight with the proteasome inhibitor Lactacystein (2
of pre-S2 domain with polyclonal anti-preS2 antibody. The location of the 36, 33, and
17 kDa polypeptides. (B) Cell lysates from panel Awere treated with either PNGase
high mannose type glycans. As before, samples were analyzed by immunoblot analy
species, which arises from the deglycosylation of the mature 36, 33, and 20 kDa protei
M protein. HepG2 cells were transfected with either the pCMV-MS expression constr
overnight with the proteasome inhibitor epoxomicin. Blots were probed with pre-S2-
probed with an HA protein-specific antibody. The full lengthM protein bands can be o
observed with and without epoxomicin treatment and indicated by the arrow. The Smulates when cells are treated with the proteasome inhibitor
(Fig. 2A). As shown in Fig. 2B, treatment with either PNGase F
or Endo H reduced both the full length 33 and 36 kDa HBV M
proteins bands to a single 30 kDa band and the 20 kDa species to
a 17 kDa species. This result indicates that, like the full-length 36
and 33 kDa HBV M species, the 20 kDa species has been in the
lumen of the ER and has become glycosylated. This result also
implies that the 17 kDa species arises from the deglycosylation
of the 20 kDa species. It is also possible that the 17 kDa fragment
arises from P30 that is formed either by the de-glycosylation of
gp33 or gp36 or from the lack of glycosylation. Prior to
degradation via the proteasomes, proteins are deglycosylated by
the action of an intracellular PNGase. Hence, inhibition of the
proteasomes often causes the accumulation of the unglycosy-
lated species (Hirsch et al., 2003).
Detection of the N-terminal and C-terminal fragments of the
HBV M protein confirms proteolytic cleavage
In an effort to further confirm that the 20 kDa pre-S2-specific
peptide was the result of proteolysis, an influenza virus
hemagglutinin (HA) epitope (YPYDVPDYASL) was placed at
the C-terminus of the HBV M protein. If the fragment observed
in Figs. 1 and 2Awas the result of a proteolytic event, then we
should be able to detect the C-terminal fragment using this
system. Thus, this vector allows the detection of the C-terminal
fragment in a conformation independent manner. This ex-2 cells were transfected with the pCMV-MS expression construct and 24 h later
0 μM). Cell lysates were then subjected to immunoblot analysis for the presence
30 kDa HBVM protein species is indicated along with the position of the 20 and
F, which removes all N-linked glycan or Endo H, which removes only hybrid or
sis with anti-preS2 antibody. The presence of the p30 and p17 HBV M protein
n species, is indicated. (C) Detection of the C-terminal fragment of cleaved HBV
uct or the pCMV-MS-HA construct and 24 h later either left untreated or treated
specific antibody as in panel A. (D) Identical samples as shown in panel C were
bserved only with the pCMV-MS-HA construct. An additional band of 13 kDa is
species are also indicated.
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was transfected into HepG2 cells as before and both the N-
terminal fragment and the C-terminal fragment detected as
shown in Figs. 2C and D using the appropriate antibody. Fig. 2C
shows the accumulation of the N-terminal fragment by
immunoblot as detected with the pre-S2-specific antibody. As
expected, both the W/T and HA tagged proteins accumulate the
pre-S2-specific N-terminal fragment following treatment with
epoxomicin. Fig. 2D shows the result of an immunoblot on the
identical samples when probed with an HA antibody. Using this
antibody, the 20 kDa fragment is not seen, providing further
evidence the 20 kDa species arises from the N-terminus of theM
protein. However, the HA tagged expression vector accumulates
a smaller 13 kDa band that is present in both untreated and
epoxomicin treated cells. As the HA tag is at the extreme
terminus of the protein, it is unlikely to arise from a DRiP but
rather is the C-terminal fragment that arises from the cleavage of
the mature M protein into two species that are subsequently
degraded by the proteasome. These fragments are specific to the
HA tagged protein as they are not observed in cells transfected
with the non-tagged M protein vectors. However, the lack of
accumulation with epoxomicin implies that this fragment is not
degraded in a proteasome dependent manner.
The N-terminal fragment is associated with membranous
fractions following microsomal analysis
To determine the intracellular location of the observed frag-
ment, we analyzed purified microsomes from cells transfected
with the W/T M expression vector in the absence or presence of
the proteasome inhibitor, epoxomicin. The top panel of Fig. 3
shows an immunoblot for the ER resident protein, calnexin, in
the soluble and pellet fractions after fractionation. As this panel
shows, calnexin is only associated with the pellet (microsome)
fraction. The location of the W/T M protein is shown on the
bottom panel in Fig. 3 as detected by immunoblot using an
antibody to the pre-S2 domain. As Fig. 3 shows that, in the
absence of the proteasome inhibitor, the W/T expression vectorFig. 3. The association of the M protein fragment with microsomes. To
determine the intracellular localization of the 17 kDa fragment, we isolated
microsomes from cells transfected with the W/T expression vector either in the
presence or absence of the proteasome inhibitor epoxomicin. ER membranes
were identified using an antibody to calnexin, an ER resident chaperone protein.
P is pellet (microsome) and S is soluble fraction. The 17 kDa fragment observed
in cells in which the proteasome is inhibited is clearly associated with the
membranous fraction.produces three bands (unglycosylated, singly glycosylated, and
doubly glycosylated isoforms) that are associatedwith the ER, as
they co-localize with the ER resident protein calnexin (Werr and
Prange, 1998). Treatment with epoxomicin did not drastically
change the relative abundance of the three W/T M protein bands
associated with the pellet fraction. However, a slight increase in
the p30 M species and a larger increase in the gp33 M species
were seen in the soluble fraction, suggesting that this was being
sent to the proteasome for degradation. In addition, the 17 kDaM
protein fragment is clearly observed and in the presence of the
proteasome inhibitor and is associated with the ER membrane,
suggesting that this peptide may have originated from the ER.
HBV M protein structural mutants produce more of the 20 and
17 kDa polypeptides
As the 20 and 17 kDa HBV-specific polypeptides accumu-
lated at late time points in pulse chase experiments (Fig. 1) and
were glycosylated (Fig. 2), it seemed possible that they were
intermediates in the degradation of the retained M protein. Thus
it was hypothesized that M protein mutants that could not be
secreted should produce more of these smaller polypeptides, if
indeed they were involved in the degradation of retained M
protein.
In an effort to determine if secretion defective forms of the
HBVM protein would produce the 20 and 17 kDa polypeptides,
we mutated several key cysteine (positions 48, 65 and 69)
residues that have been reported to prevent proper folding and
secretion (Mangold et al., 1995; Mangold et al., 1997). In 3
separate constructs, we converted each of the cysteines (C) to
alanines (A), as indicated in Fig. 4A.
All of the expression vectors were transfected into HepG2
cells as before and the level of M protein was determined by
immunoblot using an antibody to amino acids 13–26 of the pre-
S2 domain. As Fig. 4B shows that, consistent with prior reports
(Mangold et al., 1995), none of the cysteine mutants could be
secreted. That is, using a commercial ELISA kit for the HBV “a”
epitope found in all of the HBVenvelope proteins, only the W/T
expression vector secreted M protein into the culture medium
(Fig. 4B). Similar results were obtained via immunoblot analysis
(data not shown). The intracellular level of HBV M protein as
determined by immunoblot using a pre-S2-specific antibody is
shown in Fig. 4C. As this figure shows, all of the expression
vectors produced similar amounts of the full length M protein.
However, all three of the cysteine mutants produced substantial
amounts of the 20 and 17 kDa polypeptide, even in the absence
of proteasome inhibitors. This is consistent with the prediction
that causing M proteins to be detained within the cell (as, in this
case, as a consequence of preventing their secretion by structural
mutation) would lead to degradation via the 20 and 17 kDa
intermediates.
Location of potential cleavage site
Based upon the detection of the fragment with a pre-S2
antibody specific for amino acids 13–26 of pre-S2 domain, the
presence of a N-linked glycanmodification (at ASN-4 of the pre-
Fig. 4. Aberrant forms of M protein are more susceptible to degradation. (A) Secretion incompetent M protein was made by mutation of several key cysteine amino
acids. These were at positions 48, 65, and 69 of the S domain. In all cases, cysteines were converted to alanines. In addition, an expression vector lacking signal
sequence II was made to prevent entry into the ER. (B) The level of M protein associated with culture supernatant 2 days after transfection into HepG2 cells via Abbot
ELISA. (C) The level of intracellular M protein from the 5 expression vectors as detected via immunoblot using an antibody to the pre-S2 domain. As before, the
location of the mature 36, 33, and 30 kDa HBVM protein species is indicated along with the position of the 20 and 17 kDa polypeptides. (D) Northern blot analysis of
the 2.1 KB mRNA that produces the HBV M protein. As this figure shows, the mRNA levels of each construct are comparable.
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predicted that the 20 and 17 kDa polypeptides resulted from a
cleavage between amino acids 150 and 160 within the S domain.
Additionally, a computer algorithm that predicts the presence
and location of signal peptide cleavage sites in amino acid
sequences (SignalP 3.0 Server http://www.cbs.dtu.dk/services/
SignalP/) identified a potential peptidase cleavage site between
position 153–154. Thus it was hypothesized that a cleavage in
this area was responsible for formation of the 20 and 17 kDa
polypeptides.
To test the theory that cleavage of the retained protein was
occurring at this site, deletions between positions 150 and 160
within the S domain were made and the ability of this expression
vector to produce the 20 and 17 kDa polypeptides was tested.
These mutations are shown in Fig. 5A and correspond to either
complete deletions of amino acids 153–158 (pMS1) to single
amino acid substitutions of each amino acid in this stretch (pMS
4–9). Briefly, each vector, along with a WT M vector, was
transfected into HepG2 cells as before and the presence of the 20
and 17 kDa polypeptides was determined following treatment
with proteasome inhibitor by western blot using an antibody
specific for the pre-S2 domain (Fig. 5B). As expected, and
previously shown in Figs. 1–3, the WT M expression vector
accumulates the 20 and 17 kDa pre-S2-specific fragments in the
presence of inhibitors of the proteasomes. In contrast, when
amino acids between positions 153 and 158 (DYQGML) were
removed, no smaller polypeptides could be seen, either in the
presence or absence of the proteasome inhibitor epoxomicin
(MS1). Smaller mutation either prevented or reduced the
appearance of the 20 and 17 kDa polypeptides. The removalof the aspartic acid or tyrosine residue within the DYQGML
motif leads to a reduction in the appearance of the 17 kDa
fragment. In contrast removal of any amino acid within the
QGML sequence prevented the appearance of the fragment,
suggesting that these residues played a major role in the
proteolytic process. However, it is unclear what other residues
play a role in this cleavage as mutations outside of this region did
not prevent the appearance of the fragment. Treatment of cells
with either serine protease inhibitors such as TLCK had no effect
on the appearance of fragment. Furin inhibitors lead to a marked
increase in the 17 kDa fragment when added to cells or to cell
lysates before analysis, suggesting sensitivity of this fragment to
the furin proteases presents in cells and released following
production of cell lysates (data not shown).
Discussion
Most proteins that are either secreted or reside along the
secretory pathway must first traverse the membranes of the ER.
Nascent polypeptides are translocated into the ER in the
unfolded state, so folding and oligomerization occur in the
lumen of the ER. For this reason, the ER maintains chaperones
and enzymes required for folding (Helenius and Aebi, 2004).
In addition, maturation of many secretory proteins requires
posttranslational modifications that are performed by enzymes
resident in the ER. To prevent the transport of misfolded
polypeptides out of the ER, cells have evolved mechanisms to
retain misfolded proteins within the ER and to manage their
degradation (termed “ER quality control”) (de Silva et al., 1990).
Proteins irreversibly misfolded are thought to be degraded by
Fig. 5. Mutations of putative cutting site eliminate M fragmentation. (A) Based upon the size of the fragment detected with the pre-S2-specific antibody, a potential
cleavage event was predicted at positions 153–154 within the S domain of the HBV M protein. Mutations or deletions were made within this site between positions
153 and 158. In all cases of amino acid substitution, amino acids were converted to alanines. The listed construct, were introduced into HepG2 cells and the expression
of M and its cleavage product analyzed through via immunoblot using an anti-preS2 antibody. (B) The expression of the HBV M protein and its cleavage product in
untreated cultures and in cells cultured in medium containing epoxomicin for 16 h. As before, the location of the 36, 33, and 30 kDa HBV M protein species is
indicated along with the position of the 20 and 17 kDa polypeptides for each expression vector. Cleavage product was abolished with the disruption of the QGMLmotif
(mutants pMS6–9).
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2003; McCracken and Brodsky, 1996; McCracken and Brodsky,
2000; McCracken and Brodsky, 2003; Meusser et al., 2005).
While the ERAD system has been shown to be an efficient
and elegant way to handle misfolded monomeric proteins in the
ER, the degradation of aggregated proteins is more complex and
often involves the formation of inclusion bodies and multiple
methods for protein removal. In the results presented here, the
HBV M protein was retained within the ER as a particle, much
like has been observed by others with similar constructs (Sheu
and Lo, 1994). That is, we have examined the retainedM protein
by non-denaturing gel electrophoresis, which indicated that the
retained M protein was in the form of large (N200 kDa)
oligomers (data not shown). This formation may hinder their
ability to be degraded through the ERAD system. That is, as Fig.
1 shows, while a vast majority ofM protein was secreted within a
few hours after synthesis, a significant proportion was stillpresent within the cell, the levels only slightly reduced over a
period of 24 h. This process, which appears highly inefficient,
takes place over a 48-h period and leads to the formation of a
polypeptide (see Figs. 1 and 2) that was glycosylated and
accumulated in the presence of inhibitors of the cytosolic
proteasome complex. The presence of this polypeptide could not
be dismissed as just arising from DRiP, as it was glycosylated
suggesting that it had at least entered the ER. However, it is
possible that the 20 and 17 kDa polypeptides come from a
modified DRiP product, which terminates after signal sequence
II. As this polypeptide would contain signal sequences I and II, it
would still be able to enter the ER and be glycosylated. However,
this polypeptide would be considered to be misfolded and hence
it would be sent to the proteasome for degradation. In such a
model, why site-specific mutations, such as those presented in
Fig. 4, lead to a greater degree of the 20 and 17 kDa polypeptides
is unclear. In addition, why the removal of the potential cleavage
Fig. 6. Model of degradation for the HBV M protein and the generation of the
17 kDa fragment. Misfolded M protein that fails to be secreted is retained,
together with other viral surface proteins, in ER in the form of a sub-viral
particle. These aberrant M proteins are susceptible to ER protease digestion at
specific exposure site(s). Fragments generated by ER protease digestion are then
retro-translocated out of the ER through the sec-61 translocon complex for
degradation by the cytosolic proteasome for further degradation and MHC class
I presentation. Alternatively, it is possible that either the glycosylated HBV M
protein is retro-translocated out of the ER and cleaved in the cytosol giving rise
to the fragment. This fragment is then subsequently degraded via the
proteasome.
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polypeptides is also unclear.
An even more trivial explanation would be that the fragment
arises from some post lysis step. However, the accumulation of
the fragment in the presence of epoxomicin (and other
proteasome inhibitors) supports the hypothesis that the degrada-
tion of this fragment is dependent upon a functional proteasome.
In addition, incubation of cell lysates with epoxomicin (for up to
48 h) did not lead to the appearance of the fragment, suggesting
that this was indeed coming from live, intact cells.
The protease that is involved in the cleavage event is currently
under investigation and is believed to reside within the ER, as the
potential cleavage site is directly downstream of the second
major transmembrane domain and thought to be in the lumen of
the ER. Additionally, the 17 kDa fragment is associated with
microsomes (see Fig. 3). Proteases such as the kex/furins can be
ruled out, as they primarily reside in the Golgi apparatus and
inhibitors of these had no effect on the presence of the 20 kDa
fragment. Based upon the glycan analysis in Fig. 2, the
proteolytic fragment never entered the Golgi apparatus, where
complex glycan modifications are thought to occur.
It is noted that, in pulse chase experiments, the 20 kDa
polypeptide was also observed at early times points after label
had been removed. That is, as shown in Fig. 1, a small amount of
the glycosylated 20 kDa species can be observed at the 0- and 3-
h time points when the proteasome inhibitor is present. It is
hypothesized that this is the result of improper translocation into
the ER and exposure of the cleavage site, which clips the protein
and leads to the production of the fragment. Themore significant
accumulation of this fragment at the later time points suggests
that the cleavage event is involved in the degradation of retained
ER proteins. Thus this cleavage event could potentially be
utilized in several “quality control” steps.
In many ways the degradation of the HBVenvelope proteins
is similar to that of a mutant form of alpha1-Antitrypsin
(alpha1ATZ). alpha1ATZ is retained as a polymer in the endo-
plasmic reticulum (ER) of liver cells and is found in the majority
of cases of alpha1-Antitrypsin deficiency (Perlmutter, 2002).
This protein is degraded by both proteasome dependent and
proteasome independent mechanism. Similarly, our analysis has
shown that the retained HBVenvelope proteins are degraded by
the proteasome but in what appears to be a two step process. The
first is the simple retro-translocation of misfolded M protein for
direct degradation via the proteasome. That is, treatment with
proteasome inhibitor causes the slight accumulation of the
30 and 33 kDa bands, suggesting that the mature form of the
protein is being degraded by the proteasome. Second, as shown
in Fig. 6, when the HBV M protein cannot be efficiently retro-
translocated out of the ER, it is processed into fragments,
presumably in the ER by signal peptidase, before retro-
translocation and degradation via the cytosolic proteasome.
That is, the inhibition of the proteasome leads to the accu-
mulation of polypeptides of 20 and 17 kDa, which appear to arise
from a cleavage of the parent M protein. What is also not
understood is if this pathway is limited to theM protein or is also
utilized in the L and S proteins. These experiments are hampered
by the toxicity associated with the over expression of the Lprotein (Xu et al., 1997b) and the lack of available immunogenic
reagents detects the S protein in a conformation independent
manner. Although it is hypothesized that these fragments could
be the result of partial proteolysis by the proteasome, the accu-
mulation of a glycosylated species makes this unlikely, as
proteins must be de-glycosylated before entry into the protea-
some. It is also noted that all of these processes are inefficient as
the rate of degradation, as shown in Fig. 1, is slow.
The clinical consequences of this poor degradation could be
severe, as reports have indicated that pre-S1 and pre-S2
mutations, which are often associated with the development of
HCC, are retained in the ER for a prolonged period of time. This
prolonged retention leads to an ER stress response and
possibility to the eventual development of HCC (Hsieh et al.,
2004; Hung et al., 2004; Shih and Tai, 2004; Wang et al., 2005;
Xu et al., 1997b). Thus the poor degradation of these HBV
envelope proteins may have a significant clinical impact.
Materials and methods
Cell culture and plasmid transfection
HepG2 cells were cultured in 6-well plates (Corning) with
DMEM/F12 medium (Invitrogen) containing 10% fetal bovine
serum at 37 °C with 5% CO2 in circulation. For transfection of
the HBV M protein expression plasmid, HepG2 cells were
seeded onto collagen coated plates at a density of 2.5×105 per
well. At the time when cells reached 90% confluence, Fugene 6
(Roche) was used to carry out transfection of 2 μg plasmid DNA
according to the manufacturer's instruction. The proteasome
inhibitors lactacystine and epoxomicin (Calbiochem) were
76 Y. Liu et al. / Virology 369 (2007) 69–77dissolved in DMSO and applied in culture medium at con-
centration of 20 and 2 μM, respectively for 15 h or as indicated.
Plasmids construction
The HBVM and S protein sequences (nt-3174-1-1980) were
derived from ayw subtype (V01460) through pfu PCR
(Stratagene) amplification of full length viral DNA and cloned
into a pCMV-Tag4A (Stratagene) vector followed by the re-
moval of the FLAG and SV40 poly A sequences from the
backbone. This vector is referred to as pCMV-MS. In addition, a
leader sequence from human hemoglobin gene exon-1 was
added in front of the HBV surface protein open reading frame.
This causes the 2.1 kb mRNA to preferentially support the
translation of HBV middle protein.
Immunoblotting analysis
Cells in 6-well plate were lysed in 250 μl lysis buffer
consisting of 50 mM Tris–HCl, pH 7.4, 1 mM EDTA, 0.5% NP-
40, and 1× protease inhibitor cocktail (Sigma-Aldrich, St. Louis,
MO). Lysate was denatured in Laemmili buffer and resolved by
12% SDS PAGE. Proteins were blotted onto PVDF membrane
and HBV-specific polypeptides detected using a rabbit anti-
PreS2 antibody (Research Diagnostic Inc, ConcordMA) applied
at a 1:1000 dilution for 1 h followed by a 1:5000 donkey anti-
rabbit antibody conjugated with HRP (Chemicon) for 1 h.
Protein bands were visualized with ECL-plus kit (Amersham) as
done previously (Simsek et al., 2005). For detection of HA
tagged proteins, a monoclonal antibody to the HA epitope was
used at a 1:5000 dilution (Covance Inc., Berkeley, CA).
S35 labeling and immunoprecipitation
Cells in 6-well plate were washed with pre-warmed PBS
once and cultured in 1 ml DMEM labeling medium (lacking
methionine and cysteine) (Invitrogen) for 30 min. The culture
medium was then replaced with 1 ml pre-warmed DMEM
labeling medium containing 100 μCi S35-methionine/S35-
cysteine (Amersham Biosciences, Piscataway, NJ). After a 1-h
pulse, cells were chased with regular culture medium for the
indicated times (up to 48 h). Labeled cells were lysed on ice for
30 min in 750 μl pre-cold RIPA buffer (50 mM Tris–HCl, pH
7.4, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxy-
cholate, 0.1% SDS, and 1× protease inhibitor). Cell debris and
nuclei were removed by brief centrifugation at 4 °C and the
supernatants were transferred into a new tube containing 30 μl
antibody coated Protein A/G beads (Dako monoclonal 3E7 or
RDI polyclonal anti-PreS2) (Amersham). After 2 h rocking at
4 °C, the protein A/G beads were precipitated and washed 3
times with 800 μl washing buffer of 50 mM Tris–HCl, pH 7.4,
150 mM NaCl (500 mM NaCl for the last wash), 5 mM EDTA,
and 0.5% NP40. The pellet was desalted with one additional
wash with 20 mM Tris–HCl, pH 7.4, and was denatured in
40 μl 2× Laemilli loading buffer. After electrophoresis in 12%
SDS PAGE, the gel was dried and exposed to phosphor-image
(Bio-Rad).Nucleic acid analysis
Total RNA was extracted using Trizol reagent (Invitrogen).
Ten micrograms of RNA was resolved in 1.2% formaldehyde
gel and transferred to Hybond-XL membrane (Amersham).
Specific surface protein RNAwas probed with P32 labeled unit
length HBV DNA as previously described (Mehta et al., 2004).
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